Track topics on Twitter Track topics that are important to you
MISSISSAUGA, ON--(Marketwired - August 02, 2016) -
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE: MDX). The Company announces it has closed a second tranche of a previously announced non-brokered private placement. The Company raised proceeds of $165,275 to its treasury by issuance of 2,542,692 units, comprising 2,542,692 common shares and 2,542,692 share purchase warrants ("Warrants") at $0.065 per unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring August 2, 2019, at $0.14 per share. The securities issued through the private placement were subscribed for by accredited investors, and are restricted from trading before December 3, 2016.
In connection with this closing, the Company has agreed to pay a finder's fee of $6,485 in cash and 99,762 Common Share purchase warrants ("Finder's warrants") to Altus Securities Inc., with each Finder's warrant entitling the holder to purchase one common share of the Company at $0.14 during the period expiring August 2, 2019.
Following the foregoing issuance of shares in the placement, MedX has 85,054,741 shares outstanding.
The Company announced on May 30, 2016 a non-brokered private placement of a minimum of 7,692,307 units and a maximum of 23,076,923 units at a price of $0.065 per unit, for gross proceeds of a minimum of $500,000 and a maximum of $1,500,000, subject to receipt of applicable regulatory approvals including acceptance of the TSXV Venture Exchange. Each unit consists of one common share in the capital of the Company and one warrant, with each warrant exercisable into one common share at a price of $0.14 for a period of 36 months after closing. The Company announced on June 6, 2016 that it had closed a first tranche, raising proceeds of $560,400.15 to its treasury by issuance of 8,621,540 units, comprising 8,621,540 common shares and 8,621,540 share purchase warrants at $0.065 per unit. The proceeds from the private placement will be used for development of product and marketing initiatives, and general corporate expenses and working capital.
MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer with its SIAscopy technology. This technology is imbedded in its products SIAMETRICS™, SIMSYS, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIMSYS, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians and clinics, as well as being deployed in pharmacies and remote clinics from where the images are sent to dermatologists who perform a diagnosis. These products are Health Canada, FDA (US), ARTG and CE approved for use in Canada, the US, Australia, the European Union and Turkey. SIAMETRICS™ is a unique product used in a specialized market for research into the clinical effectiveness of medical treatments of certain skin conditions. MedX also designs, manufactures and distributes quality laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, to provide drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
The role of medical devices in healthcare is essential. The diversity and innovativeness of this sector contribute significantly to enhance the quality and efficacy of healthcare. Covering a wide range of products, from simple bandages to the...
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...